EATG » Cure

Cure

ABIVAX initiates clinical trial (ABX464-005) to evaluate the effect of ABX464 on HIV reservoirs in HIV patients

First patient enrolled The study seeks to unveil the biological mechanism of ABX464 behind the prolonged period before viral rebound occurs, seen in preclinical models Initial results are expected in…

April 2017 issue of Journal of Virus Eradication now online

The April issue of the Journal includes papers on a range of topics and reports from three recent meetings: R4P; Glasgow HIV; and CROI 2017. To read an overview of the…

Grant to evaluate HIV immunotherapy PENNVAX®-GP’s ability to induce HIV remission

Inovio and collaborators receive NIH grant to evaluate HIV immunotherapy PENNVAX®-GP’s ability to induce remission of HIV infection and end lifetime of drug therapy Grant will fund therapeutic clinical studies…

Hidden HIV reservoirs exposed by telltale protein

The discovery helps to identify dormant infected cells and could one day lead to a cure. Attempts to cure HIV have been thwarted by a particular type of immune-system cell…

Discovery of an HIV reservoir marker: New avenue toward eliminating the virus

French researchers have identified a marker that makes it possible to differentiate "dormant" HIV-infected cells from healthy cells. This discovery will make it possible to isolate and analyze reservoir cells…

GeoVax announces collaboration with American Gene Technologies for HIV functional cure

Clinical trial expected to commence in 2017 14 March 2017 - GeoVax Labs, Inc. (OTCQB: GOVX) announced today its collaboration with American Gene Technologies International Inc. (AGT) for the conduct…

Bone marrow transplant patient off ART for 288 days without HIV rebound

A HIV-positive bone marrow transplant recipient at the Mayo Clinic experienced prolonged viral remission lasting nearly 10 months -- longer than the so-called Boston patients -- after interrupting antiretroviral therapy…

CROI 2017: Really Rapid Review

The Conference on Retroviruses and Opportunistic Infections (CROI) returned to Seattle this past week for its 24th meeting. It's the 4th time CROI has been held in Seattle, an excellent…

How to keep HIV cure-related trials ethical: the benefit/risk ratio challenge

Re: Special Issue of the Journal of Medical Ethics on the ethics and challenges of an HIV cure For most patients with HIV who have access to antiretroviral treatment and…

Infants treated within days of birth can clear HIV reservoir rapidly

Viral load and viral DNA fall rapidly in infants who begin antiretroviral therapy (ART) within days of birth, two South African studies have found, showing the potential for clearing the…

1 9 10 11 12 13 17